Christersson, C <br/><br/>
Treatment with an oral direct thrombin inhibitor decreases platelet activity but increases markers of inflammation in patients with myocardial infarction.  [electronic resource] 

 -  Journal of internal medicine  Sep 2011 
 - 215-23 p.  digital 
<br/><br/> Publication Type: Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1365-2796 
<br/><br/><label>Standard No.: </label>10.1111/j.1365-2796.2011.02354.x  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Administration, Oral<br/>Aged<br/>Aged, 80 and over<br/>Antithrombins--administration & dosage<br/>Aspirin--administration & dosage<br/>Azetidines--administration & dosage<br/>Benzylamines--administration & dosage<br/>Biomarkers--blood<br/>Blood Platelets--drug effects<br/>C-Reactive Protein--metabolism<br/>Comorbidity<br/>Dose-Response Relationship, Drug<br/>Drug Administration Schedule<br/>Drug Therapy, Combination<br/>Female<br/>Humans<br/>Inflammation--blood<br/>Interleukin-10--blood<br/>Interleukin-18--blood<br/>Male<br/>Middle Aged<br/>Myocardial Infarction--blood<br/>P-Selectin--blood<br/>Platelet Activation--drug effects<br/>Risk Factors<br/>Thromboplastin--metabolism<br/>Time Factors<br/>Treatment Outcome